Preclinical Evidence Toward the Use of Ketamine for Recombinant Tissue-Type Plasminogen Activator-Mediated Thrombolysis Under Anesthesia or Sedation | Zendy

Clément Gakuba | Zendy; Maxime Gauberti | Zendy; Mikaël Mazighi | Zendy; Gilles Defer | Zendy; JeanLuc Hanouz | Zendy; Denis Vivien | Zendy

Open Access

Preclinical Evidence Toward the Use of Ketamine for Recombinant Tissue-Type Plasminogen Activator-Mediated Thrombolysis Under Anesthesia or Sedation

Author(s) -

Clément Gakuba,

Maxime Gauberti,

Mikaël Mazighi,

Gilles Defer,

JeanLuc Hanouz,

Denis Vivien

Publication year - 2011

Publication title -

stroke

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.397

H-Index - 319

eISSN - 1524-4628

pISSN - 0039-2499

DOI - 10.1161/strokeaha.111.620468

Subject(s) - medicine , thrombolysis , ketamine , anesthetic , anesthesia , isoflurane , propofol , sedation , tissue plasminogen activator , plasminogen activator , stroke (engine) , cardiology , myocardial infarction , mechanical engineering , engineering

Endovascular treatment of ischemic stroke usually involves recombinant tissue-type plasminogen activator (rtPA)-mediated thrombolysis in anesthetized patients. Paradoxically, differential influences of anesthetic agents on thrombolysis outcome remain unknown.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research